Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 961

Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, USA

Dr Fehrenbacher speaks with ecancer at SABCS 2017 about a phase III trial of adjuvant chemotherapy with or without trastuzumab for HER2low invasive breast cancer.

Building on findings for high HER2 patients, Dr Fehrenbacher sets out the rationale for investigating HER2 low and negative patients, as scored by FISH or IHC.
Ultimately, trial findings were negative, with trastuzumab offering no improvement for invasive disease free survival.

Watch the press conference for more. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation